Drugs / LUMROTATUG
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06285227 | Mar 2024 → Apr 2025 | — | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04818372 | Apr 2021 → Jan 2023 | plasma cell myeloma | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06663943 | Oct 2025 → Oct 2026 expected | pemphigus vulgaris | Chao Ji | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07585734 | Apr 2025 → Apr 2026 | T-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06792019 | Mar 2025 → Nov 2027 expected | blood platelet disease | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06791824 | Mar 2025 → Dec 2027 expected | aplastic anemia | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06126237 | Feb 2024 → Feb 2026 | plasma cell myeloma | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT05465707 | Oct 2022 → Oct 2023 | systemic lupus erythematosus | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06830395 | Sep 2025 → Mar 2027 expected | IgA glomerulonephritis | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06791772 | Feb 2025 → Oct 2026 expected | systemic lupus erythematosus | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06594146 | Nov 2024 → Dec 2025 overdue | autoimmune thrombocytopenia | Keymed Biosciences Co.Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06199089 | Jan → Nov 2024 overdue | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05694767 | Jan → Dec 2023 | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06904040 | Apr 2025 → Oct 2027 expected | pemphigus | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUMROTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314847 ↗ |
| Known as | CM 313 | “CM313 injection (referred to as "CM313"), developed by Keymed Biosciences (Chengdu) Co., Ltd., is a humanized monoclonal antibody with proprietary intellectual property.” NCT07585734 ↗14“treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.” NCT05694767 ↗ |
| Action | Inhibit | “This phase Ib/IIa study aimed to explore the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CM313, an anti-CD38 antibody, in patients with systemic...” PMID 41290616 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus” PMID 41290616 ↗ Nov 2025 |
| Route | Intravenous | “randomized 4:1 to receive CM313 or placebo intravenously at days 1, 29, 36, 43, and 50” PMID 41290616 ↗ Nov 2025 |
| Target | CD38 | “anti-CD38 monoclonal antibody” PMID 38899695 ↗ Jun 2024 |